Patents Examined by Reza Ghafoorian
-
Patent number: 9879252Abstract: The present invention relates to a method of identifying a protein that binds to a target molecule and has intracellular functionality. This method includes providing a construct comprising a deoxyribonucleic acid molecule encoding the protein which binds to the target molecule, with the deoxyribonucleic acid molecule being coupled to a stall sequence. A host cell is transformed with the construct and then cultured under conditions effective to form, within the host cell, a complex of the protein whose translation has been stalled, the mRNA encoding the protein, and ribosomes. The protein in the complex is in a properly folded, active form and the complex is recovered from the cell.Type: GrantFiled: July 31, 2008Date of Patent: January 30, 2018Assignee: Cornell Research Foundation, Inc.Inventors: Matthew P. Delisa, Lydia Contreras-Martinez
-
Patent number: 9873726Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.Type: GrantFiled: July 14, 2016Date of Patent: January 23, 2018Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
-
Patent number: 9873907Abstract: A method for fragmenting a genome is provided. In certain embodiments, the method comprises: (a) combining a genomic sample containing genomic DNA with a plurality of Cas9-gRNA complexes, wherein the Cas9-gRNA complexes comprise a Cas9 protein and a set of at least 10 Cas9-associated guide RNAs that are complementary to different, pre-defined, sites in a genome, to produce a reaction mixture; and (b) incubating the reaction mixture to produce at least 5 fragments of the genomic DNA. Also provided is a composition comprising at least 100 Cas9-associated guide RNAs that are each complementary to a different, pre-defined, site in a genome. Kits for performing the method are also provided. In addition, other methods, compositions and kits for manipulating nucleic acids are also provided.Type: GrantFiled: May 29, 2014Date of Patent: January 23, 2018Assignee: Agilent Technologies, Inc.Inventors: Gusti Zeiner, Derek Lee Lindstrom, Brian Jon Peter, Robert A. Ach
-
Patent number: 9868956Abstract: The invention relates to a method of making a polypeptide comprising an orthogonal functional group, said orthogonal functional group being comprised by an aliphatic amino acid or amino acid derivative, said method comprising providing a host cell; providing a nucleic acid encoding the polypeptide of interest; providing a tRNA-tRNA synthetase pair orthogonal to said host cell; adding an amino acid or amino acid derivative comprising the orthogonal functional group of interest, wherein said amino acid or amino acid derivative is a substrate for said orthogonal tRNA synthetase, wherein said amino acid or amino acid derivative has an aliphatic carbon backbone; and incubating to allow incorporation of said amino acid or amino acid derivative into the polypeptide of interest via the orthogonal tRNA-tRNA synthetase pair. The invention also relates to certain amino acids, and to polypeptides comprising same.Type: GrantFiled: June 2, 2010Date of Patent: January 16, 2018Assignees: North Carolina State University, Medical Research CouncilInventors: Duy P. Nguyen, Heinz Neumann, Alexander Deiters, Jason Chin, Hrvoje Lusic
-
Patent number: 9850525Abstract: The present invention relates to an isothermal method for detecting in a sample a target nucleic acid strand.Type: GrantFiled: January 28, 2015Date of Patent: December 26, 2017Assignee: Agilent Technologies, Inc.Inventor: Carsten-Peter Carstens
-
Patent number: 9850521Abstract: Provided herein is a reaction mixture comprising Cas9 and a non-ionic surfactant, e.g., a polyoxyethylene surfactant. In certain embodiments, the reaction mixture may comprise a Cas9 protein, a guide RNA, a salt, a buffering agent, a nucleic acid target and a non-ionic surfactant. Kits are also provided. In certain embodiments, a kit may comprise: a Cas9 protein; and a concentrated reaction buffer comprising salt, a buffering agent and a non-ionic surfactant.Type: GrantFiled: June 1, 2015Date of Patent: December 26, 2017Assignee: Agilent Technologies, Inc.Inventors: Jeffrey Carl Braman, Yuchu Grace Hsiung, Katherine Felts
-
Patent number: 9850541Abstract: The present invention relates to agents and methods for screening, diagnosis and surveillance of cancer, in particular pancreatic cancer.Type: GrantFiled: December 6, 2012Date of Patent: December 26, 2017Assignee: Valley Health SystemInventor: Ganepola A. P. Ganepola
-
Patent number: 9850483Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.Type: GrantFiled: July 19, 2011Date of Patent: December 26, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne A. Leyrat, Tomer Kalisky, Maximilian Diehn, Michael Rothenberg, Jianbin Wang, Neethan Lobo
-
Patent number: 9834820Abstract: Described herein are methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, described herein are methods of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of such a mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. Also described are compounds such as a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). Additional aspects describe an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).Type: GrantFiled: December 19, 2014Date of Patent: December 5, 2017Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique—Hopitaux de Paris (AP-HP)Inventors: Valerie Cormier-Daire, Arnold Munnich
-
Patent number: 9809858Abstract: Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy.Type: GrantFiled: April 5, 2013Date of Patent: November 7, 2017Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
-
Patent number: 9809803Abstract: This invention provides a vaccinia virus that grows specifically in a cancer cell and damages such cancer cell and the use of such virus for treatment of cancer. Such mitogen-activated protein kinase-dependent vaccinia virus strain lacks functions of vaccinia virus growth factor (VGF) and O1L, it does not grow in normal cells but grows specifically in cancer cells, and it has oncolytic properties that specifically damage cancer cells.Type: GrantFiled: November 20, 2014Date of Patent: November 7, 2017Assignees: National University Corporation Tottori University, The Chemo-Sero-Therapeutic Research InstituteInventor: Takafumi Nakamura
-
Patent number: 9810704Abstract: Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.Type: GrantFiled: February 18, 2014Date of Patent: November 7, 2017Assignee: Theranos, Inc.Inventors: Elizabeth A. Holmes, Sunny Balwani, Michael Chen, John K. Frankovich, Gary Frenzel, Samartha Anekal, Adrit Lath, Alexander Loo, Chinmay Pangarkar, Joy Roy, Timothy Smith, Daniel Young
-
Patent number: 9790554Abstract: The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject.Type: GrantFiled: August 3, 2012Date of Patent: October 17, 2017Assignee: Hummingbird Diagnostics GmbHInventors: Andreas Keller, Markus Beier, Eckart Meese, Petra Leidinger, Anke Wendschlag
-
Patent number: 9783859Abstract: A method of detecting and quantifying various enzymatic activities using a constructed artificial genetic circuit GESS (genetic enzyme screening system) for sensing phenolic compounds and a method of screening a trace of activities of target enzymes from a metagenome using the artificial genetic circuit, thereby securing target enzyme genes. When the method for screening and quantifying target enzymatic activity is used, useful genes can be screened from various genetic communities, including environmental or metagenomic libraries, at a single cell level in high throughput (million/day). Further, the sensitivity of the genetic circuit to phenol derivatives and the expression thereof can be controlled, and thus the genetic circuit can rapidly sense and quantify various enzymatic activities. Thus, the method can be advantageously used in the protein engineering technology for enzyme modification.Type: GrantFiled: June 8, 2010Date of Patent: October 10, 2017Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Seung Goo Lee, Eugene Rha, Su Lim Choi, Jae Jun Song, Jong Hyun Choi, Hee Sik Kim
-
Patent number: 9771619Abstract: An miRNA expression signature comprising a set of one or more miRNAs associated with metastatic cancer is provided. In one embodiment, the expression signature is selected from the group consisting of miR-10b, miR-139-5p, miR-130b and miR-199b-5p. In some aspects, miR-199b-5p and miR-130b are overexpressed in metastatic cancer; and miR-10b and miR-139-5p are downregulated in metastatic cancer. Such an expression signature may be used in methods for predicting metastasis, risk for developing metastasis or a prognosis in a cancer. In another embodiment, a method for establishing such a cancer miRNA expression signature is provided.Type: GrantFiled: October 28, 2011Date of Patent: September 26, 2017Assignee: CITY OF HOPEInventors: Huiqing Wu, Xiwei Wu
-
Patent number: 9771606Abstract: The genomic DNA of Streptoverticillium sp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore, Streptoverticillium sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.Type: GrantFiled: May 10, 2016Date of Patent: September 26, 2017Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Koei Kobayashi, Naomi Sumida, Koji Yanai
-
Patent number: 9758833Abstract: This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).Type: GrantFiled: February 19, 2009Date of Patent: September 12, 2017Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Stephen J. Meltzer, Yulan Cheng, Zhe Jin
-
Patent number: 9758779Abstract: The application describes a method of selecting mammalian host cells that express a polypeptide of interest with high yield. The host cells contain an expression cassette with a first polynucleotide encoding a polypeptide of interest, at least one leaky stop codon located downstream of the first polynucleotide and a second polynucleotide located downstream of the leaky codon encoding an immunoglobulin transmembrane anchor comprising a cytoplasmic domain. The host cells are cultivated to allow expression of the polypeptide of interest such that some of the polypeptides of interest are expressed as fusion proteins displayed on the cell surface. High producing cells are then selected based on the presence or amount of the displayed fusion polypeptides.Type: GrantFiled: August 28, 2009Date of Patent: September 12, 2017Assignee: Novartis AGInventors: Thomas Jostock, Hans-Peter Knopf, Burkhard Wilms, Audrey Nommay
-
Patent number: 9738687Abstract: The present description relates to synthetic peptides useful for increasing the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells. More specifically, the present description relates to synthetic peptides and polypeptide-based shuttle agents comprising an endosome leakage domain (ELD) operably linked to a cell penetrating domain (CPD), or an ELD operably linked to a histidine-rich domain and a CPD. Compositions, kits, methods and uses relating to same are also described.Type: GrantFiled: April 8, 2016Date of Patent: August 22, 2017Assignee: Feldan Bio Inc.Inventors: David Guay, Thomas Del'Guidice, Jean-Pascal Lepetit-Stoffaes
-
Patent number: 9732138Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.Type: GrantFiled: February 9, 2011Date of Patent: August 15, 2017Assignee: Yale UniversityInventors: Richard P. Lifton, Ute Scholl